I wrote to Incannex a while back, just to mention to them that if they were to develop a means of being able to control from moment to moment, the amount of psilocin affecting the patient during a session, they would probably open the door to further optimization of the therapy. Therapists could learn to recognize various inflection points where basically, the patient is 'telling' them through their behavior, brain activity and other indicators, that they are ready for the experienced to be heightened or dialed back.
It turns out Tryp Therapeutics have patented an intravenous delivery of psilocin (the metabolite of psilocybin responsible for the psychedelic effects of the medicine). This accomplishes what I had been groping for: relatively fine control over how much active metabolite is in the blood stream throughout the course of the therapy.
I wonder just how feasible it is for Tryp Therapeutics to claim proprietary status over the intravenous administration of a non-proprietary compound. I'm not a lawyer, but my guess is that this intravenous administration may become part of a broader methodology which overall confers patent protection over their therapy against those who might seek to treat the same indication as them, with similar methods. But I doubt they could prevent other companies from employing the intravenous delivery of psilocin, and I also doubt that there is anything especially challenging, technically, to practice this delivery (but I may be mistaken).
Do you think it is worth me writing to Incannex again to flag this intravenous delivery development? I mean, 100 to 1 that they are already aware. But just in case they aren't, it might be worth it. My concern is that if they establish their psiGAD therapy as the standard of care for General Anxiety Disorder, and then some company like Tryp comes along and improves upon their results by using an intravenously modulated protocol, Incannex's therapy could find itself ousted before it has had time to bask in the full limelight of its success.
However if they incorporate intravenous administration in the next phase of their trials, the approved therapy would be much more bullet proof... That's how it looks from my lay person's perspective.
Thoughts?
IHL Price at posting:
13.8¢ Sentiment: Buy Disclosure: Held
